- Details
- Laurence Albiges joins Pedro Barata to discuss the CaboPoint study, a clinical trial designed to examine the question of activity and safety of cabozantinib single agent in patients who failed first-line combination therapy for advanced renal cell carcinoma (aRCC). The study has two subgroups - Cohort A and Cohort B. Cohort A is the activity of cabozantinib after nivolumab/pembrolizumab, and Cohor...
|
- Details
- Bradley McGregor joins Pedro Barata in a conversation to discuss the results of the COSMIC-021 study, which looked at the combination of cabozantinib with atezolizumab for non-clear-cell, renal cell carcinoma. The study showed clinical activity for the combination of cabozantinib and atezolizumab across the 32 patients with variant-histology renal cell carcinoma, with no new toxicity signals. The...
|
- Details
- Alicia Morgans sits down with Thomas Powles to discuss the COSMIC-313 Phase III trial for clear cell renal cancer. Dr. Powles provides a comprehensive overview of the trial that explores a triplet of cabozantinib, ipilimumab, and nivolumab. The trial notably revealed a 25% reduction in the risk of progression, although overall survival signals were not yet evident. The data also revealed intriguin...
|
- Details
- Michael Atkins joins Pedro Barata in a conversation on Cohort A of a phase II study looking at treatment-free survival (TFS) outcomes of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260). This study was designed to potentially reduce the toxicity by sparing people ipi who didn't need it and also capping therapy in patients who were having a lo...
|
- Details
- Pedro Barata hosts Cristina Suárez to discuss the results from the CheckMate 9ER trial. The trial established the combination of Cabozantinib (Cabo) and Nivolumab (Nivo) versus Sunitinib as a standard treatment for advanced renal cell carcinoma. A post hoc analysis, categorized patients into six depth of response subgroups based on the overall response rate and tumor reduction. The findings reveal...
|
- Details
- Pedro Barata interviews Yann Vano about the BIONIKK trial, a phase two, biomarker-driven study concerning advanced clear cell renal cell carcinoma. Dr. Vano explains the methodology behind the study, which includes tumor sequencing from primary and metastatic sites. Patients are allocated to the appropriate trial cohort based on these results. Dr. Vano's team also develops a classifier of 35 genes...
|
- Details
- In a detailed discussion between Pedro Barata and Camillo Porta, they dissect the findings from the update of the CLEAR study. The study explores the effectiveness of lenvatinib and pembrolizumab versus sunitinib in treating advanced renal cell carcinoma patients. The results revealed significantly higher medium progression-free survival and overall survival rates for the lenvatinib/pembrolizumab...
|
- Details
- In this discussion, Pedro Barata and Nizar Tannir focus on the PIVOT-09 Phase III trial. They delve into the potential and challenges of the experimental combination treatment, bempegaldesleukin (BEMPEG) plus nivolumab, which showed promising initial results but was terminated due to disappointing trial outcomes. Despite this, Dr. Tannir remains optimistic about the Interleukin 2 (IL-2) pathway, p...
|
- Details
- In this conversation, Pedro Barata and Andrea Apolo highlight an exploratory analysis of the CheckMate 9ER trial in patients with previously untreated advanced renal cell carcinoma (aRCC), looking at the association between depth of response and clinical outcomes with extended follow-up (minimum 25.4 months; median 32.9 months). In January 2021, the Food and Drug Administration (FDA) approved the...
|
- Details
- Alicia Morgans interviews Toni Choueiri to discuss key topics related to kidney cancer. They delve into strategies for treating metastatic kidney cancer, focusing on combined and sequential drug approaches. Dr. Choueiri elaborates on failures and successes, particularly regarding the use of three drugs simultaneously and the importance of managing toxicity. They also discuss treatment for patients...
|
